In this phase 2 study, we evaluated the effect of letermovir (also known as AIC246), a new anti-CMV drug with a novel mechanism of action, on the incidence and time to onset of prophylaxis failure ...

Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia ...

The randomized, placebo-controlled study will evaluate the safety and efficacy of letermovir in approximately 540 patients from more than 70 centers in 20 countries, including the United States.

Additionally, treatment with letermovir was tied to lower all-cause mortality through Week 24 post transplant. “In this study, letermovir was associated with lower all-cause mortality.

The rate of myelosuppression (leukopenia or neutropenia) at 28 weeks was significantly lower with letermovir compared with valganciclovir (26% vs 64%, P<0.001), the researchers reported in JAMA. ...